Cardiovascular Health 2026

#490

Transcript Analysis and Clinical Efficacy Evaluation: Ezetimibe-Statin Combination Therapy

I. Executive Summary

The provided video transcript from the University of Kansas Health System delivers a clinical critique of combination lipid-lowering therapy based on a retrospective database analysis. The core thesis asserts that the addition of the non-statin cholesterol absorption inhibitor, ezetimibe, to a baseline statin regimen fails to provide any overall survival or all-cause mortality benefit compared to statin monotherapy alone. Although ezetimibe effectively achieves its biochemical surrogate endpoint of lowering circulating low-density lipoprotein cholesterol (LDL-C) levels, this trial demonstrates a profound disconnect between biomarker optimization and hard survival outcomes. The speaker highlights a historical translational gap driven by direct-to-consumer and medical media advertising campaigns that heavily promoted combination therapies with the clear implication of superior survival benefits before rigorous, long-term clinical trial data were matured to validate those claims.

Methodologically, this investigation represents one of the largest real-world evaluations of its era, analyzing thousands of unselected patients via electronic medical record tracking at the University of Kansas Hospital. To put these findings into modern context, contemporary high-level medical evidence validates the speaker’s assertion regarding sequential add-on therapy all-cause mortality. For instance, the landmark IMPROVE-IT randomized controlled trial and a comprehensive Cochrane systematic review confirmed that while adding ezetimibe to a statin reduces major adverse cardiovascular events—specifically non-fatal myocardial infarctions and non-fatal strokes—it has a neutral effect on all-cause and cardiovascular mortality.

Crucially, a major clinical paradigm shift has occurred: recent large-scale meta-analyses demonstrate that initiating upfront, simultaneous dual therapy with a statin and ezetimibe in very high-risk patients results in a significant nineteen percent reduction in all-cause mortality compared to traditional delayed, stepwise monotherapy titration. This underscores that the timing, risk stratification, and method of deployment are the ultimate determinants of absolute survival benefits. Therefore, while late-stage sequential ezetimibe addition remains neutral for overall lifespan extension, early upfront combination deployment provides a validated mechanism to improve healthspan and longevity by preventing cumulative, atherogenic cardiovascular events.

II. Insight Bullets

  1. Retrospective Efficacy Challenge: The University of Kansas Health System retrospective study analyzed a real-world cohort to observe the absolute long-term survivability impact of dual lipid-lowering therapy.
  2. All-Cause Mortality Neutrality: The primary clinical finding demonstrated that adding ezetimibe to standard statin therapy failed to provide an all-cause mortality or survival benefit over statin monotherapy alone in the evaluated general population.
  3. Surrogate Endpoint Disconnect: Ezetimibe successfully achieves its surrogate mechanism of lowering low-density lipoprotein cholesterol (LDL-C) by an additional 12–15%, yet this biomarker reduction did not automatically translate to an absolute reduction in death within this 2013 cohort.
  4. Media and Direct-to-Consumer Distortion: Television and medical media advertisements prominently marketed combination lipid-lowering therapies with the strong, unproven implication of superior clinical survival before long-term hard endpoint data materialized.
  5. Electronic Medical Records as Analytical Catalysts: The study demonstrates the clinical utility of large-scale Electronic Medical Records (EMRs) to rapidly track and evaluate hard clinical outcomes across unselected patient registries.
  6. Baseline Cohort Discrepancies: In the underlying peer-reviewed data published by Patel et al., 2013, the ezetimibe plus statin group was systematically younger but exhibited a significantly higher baseline incidence of coronary artery disease and prior bypass surgery.
  7. The Omega-3 and HDL Survival Signals: A critical secondary finding from the original retrospective dataset indicated that concurrent omega-3 fatty acid supplementation and higher baseline high-density lipoprotein cholesterol (HDL-C) were independently associated with substantial survival benefits.
  8. Randomized Control Trial Validation (IMPROVE-IT): Subsequent Level B evidence from the landmark IMPROVE-IT trial confirmed that adding ezetimibe to a statin safely reduces major adverse cardiovascular events (MACE) by 6.4%, driven by non-fatal myocardial infarction and stroke, but remains strictly neutral on overall and cardiovascular mortality.
  9. Cochrane Systematic Synthesis Confirmation: A comprehensive Level A meta-analysis of 26 trials involving 23,499 subjects by Preiss et al., 2018 reaffirmed that ezetimibe combined with statins yields little to no change in all-cause mortality (RR 0.98, 95% CI 0.91–1.05), matching the transcript’s primary conclusion.
  10. The Upfront Paradigm Shift: Contemporary practice-changing Level A evidence from Banach et al., 2025 reveals that upfront, simultaneous initiation of dual combination therapy (statin + ezetimibe) yields a significant 19% all-cause mortality reduction in very high-risk populations, contrasting with delayed, stepwise add-on protocols.
  11. Divergent Mechanisms of Action: Statins operate by inhibiting hepatic cholesterol synthesis via HMG-CoA reductase, whereas ezetimibe selectively blocks intestinal cholesterol absorption via the Niemann-Pick C1-Like 1 (NPC1L1) transporter, providing a complementary, non-overlapping mechanism to lower circulating atherogenic particles.
  12. Musculoskeletal Safety Profile: Large-scale meta-analyses show that adding ezetimibe to a moderate-intensity statin achieves equivalent or greater LDL-C reductions than high-intensity statin monotherapy while significantly lowering the risk of myopathy and treatment discontinuation by up to 44%.
  13. The Translational Gap in Longevity Therapeutics: The historical narrative highlights a critical translational gap where biochemical or surrogate optimization (lowering a blood marker) does not guarantee an immediate downstream extension of absolute lifespan.
  14. Cumulative Exposure (“Cholesterol-Years”): Modern longevity and cardiovascular guidelines emphasize that the absolute prevention of mortality depends heavily on reducing the lifelong cumulative exposure to atherogenic particles (“cholesterol-years”) rather than late-stage rescue interventions.
  15. Contextual Risk Stratification Necessity: The divergence between the 2013 KU retrospective data and recent meta-analyses illustrates that lipid intensification benefits are heavily concentrated in individuals at extreme or very high baseline risk of ischemic events.

IV. Actionable Protocol (Prioritized)

High Confidence Tier (Protocols backed by Level A/B evidence)

  • Upfront Dual Combination Initiation for High-Risk Cohorts: In patients with established atherosclerotic cardiovascular disease (ASCVD), a history of acute coronary syndrome (ACS), or extreme baseline cardiovascular risk, initiate a combination of a potent statin (e.g., Rosuvastatin or Atorvastatin) and Ezetimibe (10 mg/day) simultaneously at the start of care. Do not utilize the traditional 2-month delayed stepwise approach. This is proven by Level A meta-analysis data to reduce all-cause mortality by 19% and MACE by 18% [Banach et al., 2025].
  • Target Aggressive LDL-C Thresholds Early: Titrate and maintain combination therapy to drive LDL-C levels below 55 mg/dL (<1.4 mmol/L) to minimize lifelong cumulative exposure to atherogenic particles. Each 1 mmol/L (39 mg/dL) reduction in serum LDL-C corresponds directly to a 22–29% long-term reduction in major cardiovascular events [Polish Lipid Association, 2025].

Experimental Tier (Protocols backed by Level C/D evidence with high safety margins)

  • Low-Dose Statin + Ezetimibe Synergistic Protocol: For primary prevention or longevity optimization in individuals without established ASCVD but presenting with elevated ApoB/LDL-C, utilize a moderate-dose statin paired with Ezetimibe 10 mg/day instead of maximizing statin monotherapy. This protocol provides a high safety margin, achieves profound LDL-C drops, and lowers the risk of treatment discontinuation by 44% compared to high-intensity statin monotherapy [Banach et al., 2025].
  • High-Purity Omega-3 Fatty Acid Co-Supplementation: Incorporate high-dose, purified omega-3 fatty acids (specifically EPA/DHA) as an adjunct therapy. Real-world retrospective data indicates an independent survival signal associated with omega-3 use [Patel et al., 2013]; however, use highly purified pharmaceutical-grade formulations to avoid oxidized over-the-counter lipid variants.

Red Flag Zone (Claims debunked or lacking safety data)

  • Delayed Stepwise Add-on Titration for Lifespan Extension [DEBUNKED]: Relying on a slow, sequential workflow (waiting months on a statin before introducing ezetimibe) to capture all-cause mortality benefits. Level A evidence confirms this specific clinical sequence fails to alter all-cause or cardiovascular mortality rates [Preiss et al., 2018].
  • Abrupt Cessation of Ezetimibe Based on Mortality Skepticism [HIGH RISK]: Completely avoiding or discontinuing ezetimibe because it lacks independent all-cause mortality data in low-risk cohorts. Halting therapy dramatically escalates the risk of non-fatal, disabling ischemic strokes and myocardial infarctions, which are heavily prevented by the drug.
  • Unverified Natural Absorption Inhibitors [SAFETY DATA ABSENT]: Substituting validated pharmaceutical NPC1L1 inhibitors (ezetimibe) with unregulated, high-dose plant sterols or over-the-counter supplements under the assumption that they provide an equivalent cardiovascular or longevity safety profile.

Clinical Note: Scholarly Debates & Knowledge Gaps

A critical debate persists regarding the precise mechanism by which upfront combination therapy lowers all-cause mortality while late-stage sequential therapy does not. It remains an open knowledge gap whether the survival advantage of upfront dual therapy is entirely driven by reaching ultra-low LDL-C targets faster, or if ezetimibe exerts distinct pleiotropic (secondary beneficial) effects on endothelial function and plaque stabilization when administered alongside an active statin. Additional randomized controlled trials tracking long-term hard endpoints in primary prevention cohorts are required to establish whether this survival benefit extends to individuals optimizing for healthspan without pre-existing cardiovascular disease.

2 Likes
#491

HJmAb8FWsAMZDNX
HJmAb8FWsAMZDNX1920×1920 428 KB

Clinical Review: Safety and Efficacy of Ultra-Low LDL Cholesterol

Patient apprehension regarding low density lipoprotein (LDL) cholesterol reduction often conflicts with large-scale clinical data. A review published in Atherosclerosis addresses the ten most common concerns raised by patients in clinical settings regarding intensive lipid-lowering therapy (such as statins and PCSK9 inhibitors).

The 2025 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines define the optimal target for very high-risk patients as less than 55 mg/dL.

Evidentiary Breakdown of the 10 Common Patient Fears

Of the ten primary concerns raised by patients, randomized clinical trial (RCT) data confirms that eight lack supporting evidence, while two carry legitimate, quantifiable risks that require clinical management.

1. Fears Lacking RCT Evidence (8 out of 10)

  • Brain Damage / Cognitive Decline: Not supported by trial data.
  • Cancer Risk: No causal link or increased incidence demonstrated in large-scale RCTs.
  • Hormonal Disruption: Circulating LDL depletion does not compromise steroid hormone synthesis; intracellular cholesterol production remains fully intact.
  • Hemorrhagic Stroke: Aggressive lowering does not show a statistically significant increase in hemorrhagic events in primary or secondary prevention populations.
  • Muscle Destruction / Myopathy: True severe muscle damage is exceedingly rare and distinct from subjective, non-specific myalgias.
  • Nerve Damage / Peripheral Neuropathy: No structural or functional nerve degradation correlated with low LDL.
  • Immune Suppression: Cellular and humoral immunity remain unaffected by ultra-low circulating lipid thresholds.
  • Adrenal Dysfunction: Cortisol synthesis and adrenal reserve remain stable even at profound depths of LDL reduction.

2. Legitimate Concerns with Evidentiary Support (2 out of 10)

  • New-Onset Diabetes: Statins are associated with a modest, roughly 10% relative increase in incident diabetes, primarily in individuals with pre-existing metabolic risk factors. This minor elevation in risk does not outweigh the absolute cardiovascular risk reduction.
  • Fetal Harm: Statins are an established contraindication during pregnancy due to potential teratogenicity and necessity of cholesterol for fetal development.

Clinical Trial Evidence Supporting Ultra-Low LDL Targets

Large cardiovascular outcome trials enrolling tens of thousands of patients globally demonstrate that cardiovascular protection scales proportionally with lower achieved LDL levels, without introducing safety signals.

Clinical Trial Therapeutic Agent Achieved LDL Level Primary Outcomes & Safety Status
FOURIER Evolocumab (PCSK9 inhibitor) Median: 30 mg/dL 15% reduction in major adverse cardiovascular events (MACE). No adverse safety signals observed.
ODYSSEY OUTCOMES Alirocumab (PCSK9 inhibitor) Subgroups: < 25 mg/dL 15% reduction in cardiovascular mortality. No excess harm noted at ultra-low levels.
IMPROVE-IT Ezetimibe + Simvastatin Incremental lowering below statin baseline Confirmed that lower achieved LDL levels translate directly to lower event rates without safety compromises.

Clinical Takeaway

The primary clinical focus must shift from “how low is safe” to “how low saves lives.” For a patient who has suffered a myocardial infarction, maintaining an LDL level below 55 mg/dL yields a 15% to 25% relative risk reduction for a secondary major cardiovascular event.

Achieving target thresholds via guideline-directed medical therapy remains one of the most effective, evidence-based tools available to secure long-term secondary prevention and extend lifespan.

Source: https://x.com/MohammedAlo/status/2060819529651847320?s=20

4 Likes
#492

Screenshot 2026-05-31 at 12.25.08 PM
Screenshot 2026-05-31 at 12.25.08 PM1026×1064 94.8 KB

1 Like
#493

Wondering if this was th right question to answer, since it is so hard to move ACM, and statins already provide a major reduction in ACM. Statins reduce ldl by 50%, and Ezetimibe only by 15% on average, it makes sense that most of the ACM reduction in ACM is driven by statins. Not impressed at all by that study.

3 Likes
#494

Considering that life lived after a debilitating stroke generally sucks, I’d take Ezetemibe for the heart attack and stroke lowering benefits. Heart attacks cause their own problems as well such as irregular heart beats.

Also considering it’s cheap and no noticeable side effects, it’s a no-brainer in my book.

6 Likes
#495

The more I read about Ezetimibe and lipid lowering drugs the more I think they should be mandatory for everyone over 40 LOL. Benefits are HUGE and side effects negligible for most people.

1 Like
#496

Good to finally catch up… but why doesn’t everybody just target that to avoid ASCVD in the first place?

I still think the absolutely best trials are the PESA series, and they showed really convincingly that lower LDL-C, earlier in life, is better - period.

7 Likes
#497

Long story short starting at 35 IMO If you want to avoid CVD (entirely) everyone should use the appropriate dose of EZE+ best tolerated statin (my preferred is pita thanks to @CronosTempi sugestion/research for low/no risk of diabetes) to maintain a level of LDL-C under 60. Those that say LDL-C level does not matter are playing with fire LOL. Yeah, sure for some people it may not be so bad (say a level of 100) but for most people there is no denying that a level of 40-60 is a MUST. I’m not there yet but soon will, though I must admit I am at low risk since my LPa is very low naturally, I think at 11.8 last I measured. Nevertheless, I won’t take any chances.

#498

I’m not sure why people take it. It doesn’t appear on any credible anti-aging rankings, and you’ll never hear any expert or authority in the field endorse it.

Moderate- to high-quality evidence suggests that ezetimibe has modest beneficial effects on the risk of CVD endpoints, primarily driven by a reduction in non-fatal MI and non-fatal stroke, but it has little or no effect on clinical fatal endpoints.

Ezetimibe significantly reduces the risk of MI and stroke without any effect on all-cause and CV mortality and risk of cancer.

Regarding ezetimibe and telmisartan, they are indicated only for patients with severe underlying conditions, and the clinical benefits are marginal at best.

If we were to make anything mandatory for everyone over 40, metformin would be the first in line. Telmisartan or ezetimibe? They wouldn’t even make the top 1,000.

#499

Depends. If BP is above ideal (probably is for most people), then Telmisartan would be one of the most evidence based longevity interventions a person could adopt. As for metformin, there’s no evidence that it has any benefit for a healthy, non-diabetic person, and in fact there’s evidence that it may be detrimental (due to blunting positive adaptations of exercise).

3 Likes
#500

Ezetimibe monotherapy isn’t really a done thing because it isn’t very effective. However, it’s very powerful when combined with a statin, and can let you use much lower doses of both to achieve similar or greater effects.

i.e. 10mg Rosu + 10 mg Ezetimibe way outperforms 40mg of Rosu, and 5mg + 5mg probably comes close. One clear benefit is you’d experience way less statin-related side effects.

And FWIW, plenty cardiologists and lipidologists take it. I regularly go to cardiovascular conferences and meetings, have been invited to present at AHA, ISHR meetings etc, and they definitely like Ezetimibe.

UK guidelines also now support it. They used to say max out the statin dose (“maximum tolerable dose” which is a horrible idea) before add anything else. My mother was on 80mg statin (simvastatin, I think) per day for years. Since the guideline change (2023), plus a bit of pressuring the GP by saying her son is a professor in cardiovascular sciences, she’s now getting better results on 20mg statin and 10mg Ezetimibe, without the muscle cramps and liver enzyme elevations.

Ezetimibe significantly reduces the risk of MI and stroke without any effect on all-cause and CV mortality and risk of cancer.

This is said as if it’s a bad thing… but it’s basically saying that it reduces the risk of the two things which are most likely to kill you? The original trials for Ezetimibe were not well done, and it would have been almost impossible for it to have effects on all-cause mortality.

And also, I don’t see why bringing cancer into things is relevant? The whole statin preventing cancer thing is also largely noise outside of a few plausible instances (such as liver cancer), where even then it’s circumstantial and not demonstrated in any sort of proper trial.

So basically, if you believe the LDL-C → ASCVD → MI → death hypothesis (which I assume every reasonable person does) then there’s no reason to think that LDL-C lowered by Ezetimibe would be any different to it being lowered by statins, PCSK9i, BA or even plasmapheresis.

It may not be “anti-aging” but if it significantly reduces the risk of the number one most common cause of death, what’s not to love?

This may be the formal indication from the FDA (for Ezetimibe), but that’s bad advice. There’s no reason it can’t be a powerful medication for primary prevention. I’m 40, calcium score of zero, and my cardiologist recommended Ezetimibe and it works fantastically well for me.

4 Likes
#502

I like it also but don’t like the fact that interferes (however small) with physical activity/performance. Maybe Imeglimin is better of both worlds, same/similar FG lowering effect with no negative impact on physical activity/performance. And, don’t forget about EMPA or any other SGLT2i’s. Absolute must for over 40 crowd IMO.

#503

Dr. Carvalho switched to pitavastatin (welcome to the club!), after atorvastatin increased his insulin resistance, simvastatin was ineffective, and rosuvastatin increased his A1c. He also is now beating the drum for personalized medicine (welcome to the club!). He combines 2mg of pitavastatin with 10mg of ezetimibe.

Interesting video in that he emphasizes that the point of taking statins is not the lowering of LDL, but as he claims, because statins were shown to lower MACE, as there are agents that lower LDL, but not MACE.

He himself claims not to have high LDL naturally, but takes a statin not because of LDL (which is low already in his case), but because he has high Lp(a) and wants to lower his odds of MACE.

What he didn’t mention, because perhaps he is not aware of it, is that while statins raise Lp(a) by 10-20%. pitavastatin uniquely does not - perhaps if he rechecks his Lp(a) one day he might be pleasantly surprised (compared to the level on those other statins).

In any case, he got his bloodwork back and his A1c on pitavastatin dropped back down, so mission accomplished.

It seems the rest of the world (or the West) is slowly catching on to pitavastatin, and Dr, Carvalho too is spreading the word. Congrats, doc!

Doctor: My Statin Raised my Blood Sugar. Here’s How I Solved It (via Nutrition Made Simple!)

6 Likes
#504

The Vitamin K Paradox: Why Arterial Elasticity Matters More Than Calcium Plaque

For years, the longevity and biohacking communities have treated Vitamin K—particularly Vitamin K2—as a foundational tool for cardiovascular health, operating under the assumption that it acts as a molecular traffic cop, directing calcium out of the arteries and into the bones. However, a robust cross-sectional study out of Denmark provides a reality check, revealing that the relationship between Vitamin K status and vascular aging is far more nuanced than popular health narratives suggest.

The research utilized data from 2,167 older participants (mean age 68) enrolled in the 20-year follow-up of the population-based Inter99 cohort. To assess functional Vitamin K status, researchers measured plasma levels of dephospho-uncarboxylated Matrix Gla Protein (dp-ucMGP)—an inverse biomarker where higher levels indicate a functional Vitamin K deficiency. Vascular health was comprehensively evaluated using three distinct modalities: structural arterial stiffness via carotid-femoral pulse wave velocity (cfPWV), alongside coronary artery calcification (CAC) and coronary artery stenosis via advanced cardiac CT imaging.

The results decouple arterial compliance from literal plaque accumulation. After fully adjusting for age, sex, lifestyle habits, waist circumference, and kidney function, a doubling of inactive dp-ucMGP levels (reflecting lower Vitamin K status) was independently and significantly associated with increased arterial stiffness. Crucially, however, Vitamin K status showed no independent association with overall coronary artery calcification or the structural severity of coronary stenosis once these baseline metabolic and cardiovascular risk factors were accounted for.

This implies that Vitamin K’s primary vascular value may not lie in clearing out established intimal plaques within the coronary arteries. Instead, it appears to dictate the structural elasticity of the large arteries, likely by preventing calcification within the medial layer of the vessel walls—a distinct pathological process that directly impacts systemic blood pressure and cardiac workload. Furthermore, the study revealed staggering, independent correlations between functional Vitamin K deficits and metabolic derailment, including central obesity and impaired renal function, signaling that Vitamin K operates across a web of systemic longevity pathways rather than acting solely as a localized vascular shield.

Actionable Insights

  • Target Arterial Compliance, Not Plaque Reversal: If you are taking Vitamin K supplements solely to dissolve coronary artery calcium (CAC), this data suggests a reconsideration of expectations. Functional Vitamin K status does not independently correlate with localized coronary plaque burden or stenosis in a general population.

  • Quantifying the Cardiovascular Risk Impact: Every doubling of inactive dp-ucMGP levels increases structural arterial stiffness (cfPWV) by 0.30 m/s. Given that a 1.0 m/s increase in cfPWV corresponds to a 14% to 15% escalation in future cardiovascular events, maintaining optimal Vitamin K status to prevent this 0.30 m/s degradation yields an approximate 4% to 5% reduction in population-level cardiovascular risk.

  • Protect the Renal-Metabolic Axis: Optimizing Vitamin K is highly protective against systemic metabolic decay. A functional deficiency is independently associated with a 3.70-fold increased risk of central obesity and a 3.49-fold increased risk of impaired kidney function.

  • Optimize Intake Formats: Ensure consistent intake of Vitamin K1 (from leafy greens) and Vitamin K2 (menaquinones from fermented foods or targeted supplementation) to maximize the carboxylation of Matrix Gla Protein, preserving the elastic properties of large blood vessels.

Source:

  • Open Access Paper: Vitamin K status and vascular health in a general population
  • Institutions: Center for Clinical Research and Prevention, Copenhagen University Hospital (Bispebjerg and Frederiksberg), alongside Rigshospitalet and the Steno Diabetes Center Copenhagen.
  • Country: Denmark.
  • Journal Name: Nutrition, Metabolism and Cardiovascular Diseases.
  • Impact Score: The impact score of this journal is 4.0, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal.
2 Likes
#505

If we are talking about the hydrophobic menaquinones with 6 or more isoprene residues (ie not mk-4) then the argument is that they can settle into the mitochondrial membrane wall and accept electrons making the mitochondria more efficient.

#506

Screenshot 2026-06-08 at 3.44.05 PM
Screenshot 2026-06-08 at 3.44.05 PM994×650 76.3 KB

Potential of oral combination lipid‑lowering therapy beyond statins: a simulation‑based perspective from the SANTORINI study

https://www.sciencedirect.com/science/article/pii/S2666667726001819?via%3Dihub

#507

What a weird point to emphasize. Is he saying statins lower MACE independent of them lowering cholesterol?

#508

Makes sense and mace is the right outcome to look at, not ACM.

#509

Obviously I’m not in his head, but what I suppose he means, is that statins lower MACE and the fact that they lower the cholesterol number (LDL-C; ApoB) is irrelevant to him. There are drugs that lower the cholesterol number, but do not lower the rates of MACE (one example: niacin). He is focused on MACE as the operating outcome, and if statins affect that, then it’s good enough for him, and whether they simultaneously move the cholesterol number is of no importance to him. I suppose that’s another way of saying: all I care about is lowering MACE and the mechanism doesn’t matter to me. Meanwhile if all I know is that “X” lowers the cholesterol number, that tells me nothing about what interests me (rates of MACE), therefore I don’t care about it.

2 Likes
#510

Butyrate Reverses Structural and Inflammatory Hallmarks of the Aging Heart